An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)

Abstract

Ash Bullement,1 Emma S Knowles,1 Merel Langenfeld,2 Gil Reynolds Diogo,3 Jameel Nazir,4 Daniel Eriksson4 1Delta Hat, Nottingham, UK; 2Sobi, Woluwe-Saint-Lambert, Belgium; 3Sobi, Cambridge, UK; 4Sobi, Stockholm, SwedenCorrespondence: Daniel Eriksson Email [email protected]: Systemic juvenile idiopathic arthritis (sJIA) is a rare, complex autoinflammatory disease with substantial morbidity, often characterized by fever, rash, and muscle pain, amongst other symptoms. Biologic agents, such as anakinra, have been successfully used to treat patients internationally, but their usage in some regions is limited to patients that have failed to achieve clinically inactive disease with corticosteroids and conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Use of anakinra early in the disease course leads to better clinical outcomes; however, longer-term costs for this treatment strategy have not been established. This study compares the economic implications of first-line versus later-line availability of anakinra for patients with sJIA.Methods: Data for patients treated with first-line anakinra were identified from a single-center, prospective study and compared to a combination of published trial and economic evaluation information to facilitate a comparison to later-line anakinra (ie, following corticosteroids + csDMARDs). Costs were estimated for product acquisition and medical resource utilization (MRU), including planned outpatient visits and unplanned hospital admissions. Total costs over a 5-year horizon were compared.Results: Total 5-year product acquisition cost for the first-line anakinra strategy was € 24,021, and for later-line anakinra was € 20,471. The corresponding MRU costs were € 19,197 (first-line) versus € 25,425 (later-line). Overall 5-year costs (product acquisition and MRU) were lower for the first-line strategy (€ 43,218 versus € 45,896).Conclusion: The use of anakinra for patients with sJIA in the first-line setting is efficacious to induce and sustain inactive disease, and the findings of this study show that this treatment strategy leads to cost savings through reduced medical expenditure.Keywords: Still’s disease, systemic juvenile idiopathic arthritis, anakinra, economic comparison, treatment strategies, first line

Keywords

• still’s disease
• systemic juvenile idiopathic arthritis
• anakinra
• economic comparison
• treatment strategies
• first line.